Neutralizing antibodies in multiple sclerosis patients treated with 375 μg interferon-β-1b-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Neutralizing antibodies in multiple sclerosis patients treated with 375 μg interferon-β-1b

Published:2009-03-11 Issue:4 Volume:9 Page:387-397
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Durelli L,Barbero P,Cucci A,Ferrero B,Ricci A,Contessa G,De Mercanti S,Ripellino P,Lapuma D,Viglietta E,Bergui M,Versino E,Clerico M

Publisher

Informa Healthcare

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

http://www.tandfonline.com/doi/pdf/10.1517/14712590902762781

Reference65 articles.

1. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial

2. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial

3. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis

4. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

5. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis;CNS Drugs;2022-05-19

2. The proportion of myeloid-derived suppressor cells in the spleen is related to the severity of the clinical course and tissue damage extent in a murine model of multiple sclerosis;Neurobiology of Disease;2020-07

3. Clinical utility of anti-interferon-beta antibodies in patients with multiple sclerosis;Aktualności Neurologiczne;2016-06-30

4. Development of interferon beta-neutralising antibodies in multiple sclerosis—a systematic review and meta-analysis;European Journal of Clinical Pharmacology;2015-08-14

5. Advances in T Helper 17 Cell Biology: Pathogenic Role and Potential Therapy in Multiple Sclerosis;Mediators of Inflammation;2015

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3